Alaskan Malamute Polyneuropathy (AMPN)

Quick Summary

Alaskan Malamute polyneuropathy is an inherited neuromuscular defect of varying severity most often characterized by abnormal changes in the dog's gait and mobility.

Phenotype: Signs of Alaskan Malamute polyneuropathy (AMPN) can include exercise intolerance, change in bark, noisy breathing, muscle atrophy, and progressive gait abnormalities of hind legs. Signs of the disease appear between 3-19 months of age and can range from mild to severe. Affected dogs may have difficulty standing and walking up stairs.

Mode of Inheritance: Autosomal recessive

Alleles: N = Normal, AMP = Alaskan Malamute polyneuropathy

Breeds appropriate for testing: Alaskan Malamute

Explanation of Results:

  • Dogs with N/N genotype will not have Alaskan Malamute polyneuropathy and cannot transmit this variant to their offspring.
  • Dogs with N/AMP genotype will not be affected by Alaskan Malamute polyneuropathy, but are carriers. They will transmit this variant to 50% of their offspring. Matings between two carriers are predicted to produce 25% Alaskan Malamute polyneuropathy-affected puppies.
  • Dogs with AMP/AMP genotype will have Alaskan Malamute polyneuropathy, a neuromuscular disease.

Results of this test can be submitted to the OFA (Orthopedic Foundation for Animals)

Price

$50 one test per animal
$30 as additional test (same animal)
$45 for 3 or more dogs

Additional Details

Alaskan Malamute Polyneuropathy (AMPN) is an inherited neuromuscular defect. Signs can include exercise intolerance, change in bark, noisy breathing, muscle atrophy and progressive gait abnormalities of hind legs. Signs of the disease appear between 3-19 months of age and can range from mild to severe. Affected dogs may have difficulty standing and walking up stairs.

AMPN is caused by a mutation in the N-myc downstream-regulated gene (NDRG1). It is inherited as an autosomal recessive, thus both females and males can be affected if they carry 2 copies of the defective gene. Animals with 1 copy are not affected but are carriers. Breeding two carriers together is predicted to produce 25% affected offspring and 50% carriers of the disease.

Testing for AMPN assists owners and breeders in identifying affected and carrier dogs. Breeders can use results from the test as a tool for selection of mating pairs to avoid producing affected dogs.

 

Note: This test is specific for the AMPN mutation described in Alaskan Malamutes.
Turnaround Time
3-6 business days

Species

Dog

Type of Test

Results Reported As
Test Result Alaskan Malamute Polyneuropathy
N/N Normal. No copies of AMPN mutation.
N/AMP Carrier. 1 copy of AMPN mutation. Dog is normal. Breedings between carriers are expected to produce 25% affected puppies.
AMP/AMP Affected. 2 copies of AMPN mutation.
References

Bruun, C.S., Jäderlund, K.H., Berendt, M., Jensen, K.B., Spodsberg, E.H., Gredal, H., Shelton, G.D., Mickelson, J.R., Minor, K.M., Lohi, H.T., Bjerkås, I., Stigen, Ø., Espenes, A., Rohdin, C., Edlund, R., Ohlsson, J.A., Cizinauskas, S., Leifsson, P.S., Drögemüller, C., Moe, L.C., Cirera, S., & Fredholm, M. (2013). A Gly98Val Mutation in the N-Myc Downstream Regulated Gene 1 (NDRG1) in Alaskan Malamutes with Polyneuropathy. PloS One 8(2): e54547. doi: 10.1371/journal.pone.0054547